Evidence map›Paper›PMID 41013439›Full record

ArticleBMC oral health2025

Antifungal efficacy of cinnamaldehyde and nano-cinnamaldehyde particles against candidiasis: an in-vitro study.

Tahereh Molania, Majid Saeedi, Katayoun Morteza-Semnani, Reza Negarandeh, Abolfazl Hosseinnataj, Anahita Lotfizadeh, Hossein Fadaei, Ali Jafari, Maede Salehi, Iman Haghani

Abstract read
In one paragraph

Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Frontiers in pharmacology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tahereh MolaniaDepartment of Oral Medicine, Dental Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Majid SaeediDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Katayoun Morteza-SemnaniDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Reza NegarandehPharmaceutical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Abolfazl HosseinnatajDepartment of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Anahita Lotfizadeh, Dentist, Sari, Iran.
Hossein Fadaei, Dentist, Sari, Iran.
Ali Jafari, Dentist, Sari, Iran.
Maede SalehiDepartment of Oral Medicine, Dental Research Center, Mazandaran University of Medical Sciences, Sari, Iran. salehimaede1165@gmail.com.
Iman HaghaniInvasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. imaan.haghani@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCandidiasis is humans' most common oral fungal infection and is a major opportunistic fungal infection with significant morbidity and mortality, particularly in immunocompromised patients, highlighting its clinical importance worldwide. This study investigated the antifungal effect of nystatin, fluconazole, cinnamaldehyde, and nano-cinnamaldehyde on candidiasis.

methodsIn this in vitro study, nano-cinnamaldehyde formulations were prepared using span60, tween60, and cholesterol for fabrication of noisome vesicles by the ethanol injection technique. The optimum formulation (cinnosome 2) was prepared with 100 mg Span 60, 100 mg Tween 60, and 50 mg cholesterol with 5 ml of ethanol. The size and particle dispersion index (PDI) of nanoparticles were measured using Dynamic Light Scattering technique, the zeta potential was measured using Zetasizer Nano ZS, and the amount of nano-cinnamaldehyde release was measured using dialysis by USP2 dissolution device. Twenty Candida species isolates, including C. albicans, Pichia kudriavzevii, Nakaseomyces glabratus, and C. tropicalis, were obtained from clinical samples, cultured in malt extract agar medium, and fungal suspensions were prepared in RPMI medium. For antifungal evaluation, the broth microdilution test was performed, and the MIC was read after 24 h. Differences between groups were determined by Mann-Whitney and Kruskal-Wallis tests at a significance level of 0.05 via GraphPad Prism 6 and SPSS 22 software.

resultsAmong the five niosomal formulations, the optimal nanoparticle showed a mean size of 228.75 ± 2.38 nm, PDI of 0.24 ± 0.01, zeta potential of -10.87 ± 1.09 mV, and encapsulation efficiency (EE%) of 66.71 ± 3.93%. The size of the nanoparticles varied from 137 to 297 nm among the formulations, and the particle size increased significantly with the amount of cholesterol. Nystatin, fluconazole and nano-cinnamaldehyde showed the best antifungal property with the lowest geometric mean (GM), 0.177 µg/mL, 0. 308 µg/mL and 0.554 µg/mL, respectively, followed by cinnamaldehyde (2.732 µg/mL) and carrier (2.828 µg/mL).

conclusionsAccording to the MIC CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

AcroleinAntifungal AgentsCandidaNanoparticlesFluconazoleHumansIn Vitro TechniquesMicrobial Sensitivity TestsNystatinParticle SizeAcroleinAntifungal AgentscinnamaldehydeFluconazoleNystatinAntifungal activityCandidiasisCinnamaldehydeNanoparticleNoisome

Identifiers

PMID41013439
PMCPMC12465914

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.